We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.44%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$952M
AUM Growth
+$53.7M
Cap. Flow
-$41M
Cap. Flow %
-4.31%
Top 10 Hldgs %
58.55%
Holding
72
New
9
Increased
10
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$17.9M
2
PCYC
PHARMACYCLICS INC
PCYC
+$11.9M
3
IBB icon
iShares Biotechnology ETF
IBB
+$11.1M
4
INCY icon
Incyte
INCY
+$7.27M
5
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$6.88M

Top Sells

Rank Stock Value
1
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
+$16.3M
2
PBYI icon
Puma Biotechnology
PBYI
+$16M
3
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$15.5M
4
MRK icon
Merck
MRK
+$14.1M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$9.41M

Sector Composition

Rank Sector Weight
1 Healthcare 89.95%
2 Miscellaneous 8.27%
3 Financials 1.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MCK icon
26
McKesson
MCK
$104B
$9.18M 0.96%
56,862
– –
IRWD icon
27
Ironwood Pharmaceuticals
IRWD
$692M
$8.92M 0.94%
917,052
– –
FRX
28
DELISTED
FOREST LABORATORIES INC
FRX
$8.79M 0.92%
146,500
– –
IPXL
29
DELISTED
Impax Laboratories, Inc.
IPXL
$8.66M 0.91%
344,683
– –
ENDP
30
DELISTED
Endo International plc
ENDP
$8.51M 0.89%
126,215
– –
SGNT
31
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$8.1M 0.85%
319,231
+49,200
+18% +$1.11M
ALKS icon
32
Alkermes
ALKS
$7.73B
$7.92M 0.83%
194,870
– –
CTRX
33
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$6.93M 0.73%
+146,000
New +$6.88M
ARAY icon
34
Accuray
ARAY
$27.8M
$6.38M 0.67%
731,943
– –
UNH icon
35
UnitedHealth
UNH
$340B
$6.21M 0.65%
82,436
– –
IDXX icon
36
Idexx Laboratories
IDXX
$40.9B
$5.99M 0.63%
112,530
– –
IPCI
37
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$5.2M 0.55%
140,400
-33,100
-19% -$888K
INFI
38
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.83M 0.51%
349,899
– –
MACK
39
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$4.04M 0.42%
96,221
-32,074
-25% -$930K
NBIX icon
40
Neurocrine Biosciences
NBIX
$15.3B
$4M 0.42%
427,790
-142,597
-25% -$1.39M
CVS icon
41
CVS Health
CVS
$119B
$3.84M 0.4%
53,694
– –
MOH icon
42
Molina Healthcare
MOH
$10.7B
$3.65M 0.38%
+105,000
New +$3.54M
AUXL
43
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$3.59M 0.38%
173,020
-77,000
-31% -$1.45M
CNC icon
44
Centene
CNC
$33B
$3.54M 0.37%
+240,000
New +$3.59M
BDSI
45
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.43M 0.36%
+581,860
New +$3M
ACOR
46
DELISTED
Acorda Therapeutics
ACOR
$3.3M 0.35%
941
– –
ALNY icon
47
Alnylam Pharmaceuticals
ALNY
$32.2B
$3.13M 0.33%
48,695
+24,950
+105% +$1.49M
CLVS
48
DELISTED
Clovis Oncology, Inc.
CLVS
$1.97M 0.21%
32,658
+9,971
+44% +$542K
LITS
49
Lite Strategy Inc
LITS
$35.4M
$1.95M 0.21%
12,196
– –
NPSP
50
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$1.91M 0.2%
62,800
+1,940
+3% +$53.4K
1
2
3

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, Tekla Capital Management held 72 positions worth $952M, up 6% from $899M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Tekla Capital Management withdrew a net $41M in Q4 2013, closing 15 positions and reducing 8 holdings. Its most notable exit was WARNER CHILCOTT PLC ORD SHS CL A (IRL), an estimated $16.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Tekla Capital Management opened a new position in PHARMACYCLICS INC worth $10.4M.

  • Tekla Capital Management's largest Q4 2013 buy was PHARMACYCLICS INC: 98,000 shares worth $10.4M.
  • Tekla Capital Management added most to Allergan plc in Q4 2013, an estimated $17.9M increase.
  • Tekla Capital Management's biggest Q4 2013 reduction was Puma Biotechnology, cutting an estimated $16M.
  • Tekla Capital Management fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $16.3M.
  • Tekla Capital Management's ten largest holdings make up 59% of its $952M portfolio in Q4 2013.
  • Tekla Capital Management opened 9 new positions and closed 15 in Q4 2013.
  • Tekla Capital Management's portfolio value rose 6% quarter-over-quarter to $952M.

Based on Tekla Capital Management's 13F filing for Q4 2013, filed 28 Jan 2014.